在晚期肺腺癌中使用sunvozertinib单疗法,EGFR20插入和高PD-L1表达:一个病例报告
1Department of Oncology, Liaocheng People's Hospital, Liaocheng City, Shandong Province, 252000, People's Republic of China.
Cancer management and research
|September 24, 2025
概括
桑沃泽提尼布作为非小细胞肺癌 (NSCLC) 的第一线治疗方法具有前皮生长因子受体 (EGFR) 插入的前20的承诺. 这种向疗法在无法容忍初始治疗的患者中提供了长时间的无进展生存和可管理的安全性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮表皮生长因子受体 (EGFR) 异构20插入突变是非小细胞肺癌 (NSCLC) 的关键驱动因素,影响2-5%的EGFR突变病例.
- 这些突变赋予了对常规EGFR氨酸激酶抑制剂 (TKI) 的耐药性.
- 桑沃泽提尼布 (Sunvozertinib) 是中国批准的EGFR-TKI,用于二线治疗EGFR外20插入突变的NSCLC.
研究的目的:
- 评估sunvozertinib作为一种维持疗法,用于患有NSCLC和EGFR外因子20插入的患者,这些患者对一线免疫化学疗法不耐受.
- 评估sunvozertinib在这种特定的临床场景中的疗效,安全性和耐受性.
主要方法:
- 病例报告,详细说明单个患者的治疗过程.
- 患者在初始免疫化学疗法不耐受后接受了sunvozertinib作为维持疗法.
- 监测了无进展的生存,安全性和耐受性.
主要成果:
- 桑沃泽提尼布维持治疗导致了长时间的无进展生存.
- 治疗表明可管理的安全性和耐受性.
- 这表明sunvozertinib的潜在疗效超出了二线治疗.
结论:
- 桑沃泽提尼布可以成为NSCLC患者的可行和有效的治疗选择,这些患者患有EGFR外基因组20插入突变,特别是那些不能耐受标准一线疗法的人.
- 这些发现支持研究sunvozertinib作为这种患者群体的潜在一线治疗选择.
- 桑沃泽提尼布为具有挑战性的NSCLC患者提供了一个有前途的治疗策略.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.2K
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.8K
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
441
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441
01:27Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K